Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06345001 | A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers | completed | Phase 1 | 14 | BayerINDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06916546 | SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC | completed | — | 238 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Apr 8, 2025 |
| clinicaltrials |
| NCT04602026 | The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer(RIOT) | completed | N/A | 66 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06003218 | Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation | completed | N/A | 88 | Peking University First HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04316182 | Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)(ACTION) | completed | Phase 2 | 24 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06899763 | Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy(1003rcr2022_72) | completed | — | 6 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06416683 | Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)(ABCHCaen) | completed | — | 109 | University Hospital, CaenOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06503250 | A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization | completed | — | 113 | Hoffmann-La RocheINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04484636 | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)(PLATON) | completed | N/A | 400 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05250895 | BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy | completed | Early Phase 1 | 9 | Emory UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04401800 | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | completed | Phase 2 | 64 | BeiGeneINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03397654 | Study of Pembrolizumab Following TACE in Primary Liver Carcinoma(PETAL) | completed | Phase 1 / Phase 2 | 26 | Imperial College LondonOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04710641 | Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone(OUTREACH2) | completed | Phase 2 | 8 | Mina Alpha LimitedINDUSTRY | 2 | Mar 6, 2025 | clinicaltrials |
| NCT05233098 | TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. | completed | — | 6 | Boston Scientific CorporationINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT04297280 | TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma | completed | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)(GLYCAR) | completed | Phase 1 | 9 | Baylor College of MedicineOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04948697 | A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | completed | Phase 2 | 94 | BeiGeneINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT05010668 | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 28 | Fudan UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04022746 | An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer | completed | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06037343 | Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRI | completed | — | 50 | Central Hospital, Nancy, FranceOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05236699 | A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC(CCGLC-005) | completed | Phase 2 | 23 | Tongji HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05162352 | Donafenib Plus Sintilimab for Advanced HCC | completed | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03439891 | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 16 | Robin Kate KelleyOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04361331 | Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 61 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT01804166 | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | completed | Phase 4 | 1 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT04511455 | Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment | completed | Phase 2 | 22 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04522908 | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06720675 | Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence | completed | — | 237 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05431621 | Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers | completed | — | 2,430 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05848947 | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA(MAApping) | completed | Phase 4 | 5 | Sirtex MedicalINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06799468 | Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation(TRAIN-AI) | completed | — | 1,769 | European Hepatocellular Cancer Liver Transplant GroupOTHER | 0 | Jan 29, 2025 | clinicaltrials |
| NCT05462314 | Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies | completed | — | 24 | ViomeINDUSTRY | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT04767906 | Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors(CaPture) | completed | Phase 2 | 16 | University of LeipzigOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06789224 | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device(REMOVE) | completed | N/A | 136 | Lindis Bloodcare GmbHINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06776185 | Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma | completed | — | 3,000 | Chen XiaopingOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06775158 | Perioperative Myocardial and Renal Injury in Patients Undergoing Hepatic Resection | completed | — | 128 | Istanbul Saglik Bilimleri UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04272619 | Liver Cancer Community Education | completed | N/A | 67 | Fox Chase Cancer CenterOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06760494 | Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With Explainability(MAPUSE) | completed | — | 250 | Chinese PLA General HospitalOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03756051 | Harms of Hepatocellular Carcinoma Surveillance | completed | — | 2,871 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04802954 | Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients(STARHE) | completed | N/A | 400 | IHU StrasbourgOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT01640522 | Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms(CaSSY) | completed | N/A | 261 | University of PittsburghOTHER | 1 | Dec 13, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 13, 2025source: clinicaltrials